Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Merck Group announced on Wednesday, March 24, that it has assigned a new chief financial officer. The company picked Caroline Litchfield to be Robert Davis’s replacement and she will assume her post starting April 1.
Litchfield’s new appointment at the company
As per Reuters, Litchfield has been working for Merck since 1990. At that time, she joined the company as part of its unit in the U.K. Prior to her new assignment as CFO this year, she was in charge of Merck’s treasury, tax and investor relations.
She has also worked in the financial operations section for Merck’s Human Health. This unit is the pharmaceutical firm’s largest business to date.
In any case, she will be succeeding Rob Davis, who will leave his post as CFO. He will be taking over as the company’s new chief executive officer as the current CEO, Ken Frazier, already announced last month that he is retiring in June.
Litchfield’s expected contribution as the new CFO
The new assignments of chief officers also come as Merck is aiming for transformation. It wanted to diversify its offerings and go beyond the immuno-oncology business development. It was mentioned that Litchfield would be a big help in this transition as she takes on part of the responsibilities for this plan.
“Caroline’s appointment as our next CFO is the result of a combination of factors and most importantly, Caroline’s financial expertise, remarkable track record, and leadership as well as our commitment to developing talent and our succession planning for leadership roles,” Kenneth C. Frazier said in a press release.
Davis added, “Caroline’s passion for Merck’s mission and for the patients we serve guides every decision that she makes." He said he is also looking forward to working with Caroline and "to benefit from her expertise and leadership as we chart the course for Merck in the months and years ahead.”
In response to the warm welcome from her colleagues, Caroline Litchfield said that she is very honored to serve Merck as the new CFO. She went on to say that her assignment is even more meaningful as it comes at such a pivotal time when the company is transitioning to improve lives.
